^(188)Re-7E11C5.3在前列腺癌裸鼠模型中的放射免疫治疗研究  

^(188)Re-7E11C5.3 radioimmunotherapy on human prostate cancer xenograft in nude mice

作　　者：张勇[1] 许杰华[1] 陈维真[1] 卢汉平[2] 梁昌盛[3] 邹俊涛[4] 谢瑶[4] 刘长征[2] 

机构地区：[1]中山大学附属第三医院核医学科,广州510630 [2]中山大学基础医学院实验核医学教研室,广州510080 [3]中山大学基础医学实验教学中心,广州510080 [4]中山大学基础医学院人体解剖学教研室,广州510080

出　　处：《核技术》2008年第8期616-618,共3页Nuclear Techniques

基　　金：广东省科技计划项目(2003B30103;2007A060305011)资助

摘　　要：为探讨188Re标记前列腺特异膜抗原单克隆抗体7E11C5.3放射免疫治疗前列腺癌裸鼠移植瘤的效果,将32只荷LNCaP移植瘤裸鼠随机分成4组:188Re-7E11C5.3组、188Re-mIgG组、188ReO4-组和对照组,采用5.55MBq单剂量尾静脉注射给药,连续4周观察裸鼠体重和肿瘤体积变化。实验结束后,检测裸鼠血清PSA水平,测定移植瘤重量,计算抑瘤率。结果显示,188Re-7E11C5.3组的瘤体重量和动物血清PSA水平均小于对照组(P<0.01),抑瘤率为60.7%。188Re-mIgG组和188ReO4-组的瘤体重量和裸鼠血清PSA水平与对照组相比差异均无统计学意义(P>0.05)。结果表明,188Re-7E11C5.3能有效抑制前列腺癌裸鼠移植瘤的生长,具有较好的抗前列腺癌应用前景。Abstract To evaluate the effect of ^188Re-7E11C5.3 radioimmunotherapy on human prostate cancer, 32 nude mice bearing LNCaP xenograft tumor were randomized into four groups, i.e. the ^188Re-7E11C5.3, the ^188Re-mIgG and the ^188ReO4^- groups, plus the control group. After 5.55 MBq single dose intravenous injection through the tail, changes in body weight and the tumor volume were monitored for four consecutive weeks. The serum PSA levels were detected. The tumors were weighed and inhibitory rate of the tumor growth was calculated. The results showed that the tumor weight and serum PSA level of the mice were significantly lower in ^188Re-7E11C5.3 group than those in the control group （P〈0.01）. The inhibitory rate of tumor growth was 60.7% in the ^188Re-7E11C5.3 group. There was no significant difference of tumor weight and serum PSA level among ^188Re-mIgG, ^188ReO4^- and control groups（P〉0.05） In conclusion,^188Re-7E11C5.3 can effectively inhibit the growth of xenografted human prostate cancer and may be a suitable radiopharmaceutical for the treatment of prostate cancer.

关 键 词：前列腺癌 抗体 单克隆 铼-188 放射免疫疗法 

分 类 号：R737.25[医药卫生—肿瘤]